"10.1371_journal.pone.0042345","plos one","2012-08-03T00:00:00Z","Helen Heyerdahl; Nasir Abbas; Ellen Mengshoel Brevik; Camilla Mollatt; Jostein Dahle","Department of Radiation Biology, Institute for Cancer Research, Oslo University, Hospital - The Norwegian Radium Hospital, Oslo, Norway; Department of Research and Development, Algeta ASA, Oslo, Norway; Department of Research and Development, Nordic Nanovector AS, Oslo, Norway","Conceived and designed the experiments: HH JD. Performed the experiments: HH EMB CM NA. Analyzed the data: HH NA JD. Contributed reagents/materials/analysis tools: EMB. Wrote the paper: HH JD EMB. Performed radiolabeling including analysis of specific activity and IRF: EMB. Critical revision of dedicated parts of the manuscript: NA CM.","Ellen M. Brevik is an employee of Algeta ASA. Algeta has approved patents and pending patent applications: Regarding thorium-227 conjugates, deriving from the PCT application WO01/39806 A1, and regarding using thorium-227 therapy, deriving from the PCT application WO04/091668 A1. There are presently no products in Development relating to these patents or patent applications. The current study is not part of any thorium-227 development program; however Algeta supported this study by providing the 227Th-DOTA-p-benzyl-trastuzumab and some material cost according to a collaboration agreement between Algeta and the Norwegian Radium Hospital. EMBs contribution to the study was performance of the radiolabeling including analysis of specific activity and IRF, and contribution to manuscript writing of these specific parts of the manuscript describing the radiolabeling and IRF procedure. Jostein Dahle owns a small amount of shares in Algeta ASA. There are no further interests to declare with regards to employment, consultancy, patents or products in development. Jostein Dahle was until January 2011 heading the Radioimmunotherapy group at Department of Radiation Biology, Institute for Cancer Research. His current employer Nordic Nanovector is independent of Algeta ASA and Nordic Nanovector is not a sponsor of the current study. The above does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","08","Helen Heyerdahl","HH",5,TRUE,2,4,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
